

Sebastian Theurich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/338220/publications.pdf>

Version: 2024-02-01

114
papers

4,025
citations

136950

32
h-index

123424

61
g-index

129
all docs

129
docs citations

129
times ranked

8010
citing authors

#	ARTICLE	IF	CITATIONS
1	Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE3 (AIO KKR0306). <i>International Journal of Cancer</i> , 2022, 150, 112-123.	5.1	10
2	Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies. <i>Haematologica</i> , 2022, 107, 2096-2107.	3.5	17
3	Two-dimensional CT measurements enable assessment of body composition on head and neck CT. <i>European Radiology</i> , 2022, 32, 6427-6434.	4.5	4
4	Checkpoint-inhibitor induced Polyserositis with Edema. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 3087-3092.	4.2	3
5	Indolent Cutaneous T-Cell Lymphomas. <i>Hematologic Malignancies</i> , 2021, , 209-230.	0.2	0
6	Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM. <i>Cancers</i> , 2021, 13, 1322.	3.7	6
7	Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on 18F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression. <i>Diagnostics</i> , 2021, 11, 423.	2.6	1
8	Long-term physical training in adolescent sprint and middle distance swimmers alters the composition of circulating T and NK cells which correlates with soluble ICAM-1 serum concentrations. <i>European Journal of Applied Physiology</i> , 2021, 121, 1773-1781.	2.5	3
9	High-resolution spatiotemporal pHe and pO2 imaging in head and neck and oesophageal carcinoma cells. <i>Cancer & Metabolism</i> , 2021, 9, 21.	5.0	3
10	Treatment-specific evaluation of the modified Glasgow Prognostic Score in patients with advanced cutaneous melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e879-e883.	2.4	3
11	Treatment of Refractory High-Flow Chylothorax in High-Grade B-Cell Lymphoma by Intratumoral Lymphatic Embolization. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 2002-2004.	2.0	0
12	Treatment-Free Intervals during CD19xCD3 BiTE [®] Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cells. <i>Blood</i> , 2021, 138, 513-513.	1.4	0
13	Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of Targeted Therapies. <i>HemaSphere</i> , 2021, 5, e664.	2.7	0
14	Disrupting Roquin-1 interaction with Regnase-1 induces autoimmunity and enhances antitumor responses. <i>Nature Immunology</i> , 2021, 22, 1563-1576.	14.5	22
15	CD33 BiTE [®] Construct Mediated Immunological Synapse Formation and Downstream Signaling in T Cells Is Dependent on Expression of Costimulatory Molecules on Target Cells. <i>Blood</i> , 2021, 138, 2237-2237.	1.4	1
16	Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 2020, .	2.8	21
17	Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. <i>Leukemia</i> , 2020, 34, 1177-1181.	7.2	6
18	Single-slice CT measurements allow for accurate assessment of sarcopenia and body composition. <i>European Radiology</i> , 2020, 30, 1701-1708.	4.5	57

#	ARTICLE	IF	CITATIONS
19	Evaluating body composition by combining quantitative spectral detector computed tomography and deep learning-based image segmentation. <i>European Journal of Radiology</i> , 2020, 130, 109153.	2.6	16
20	Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. <i>Haematologica</i> , 2020, 105, 2872-2878.	3.5	40
21	P01.18â€¦Metabolic status and immune activation influence clinical outcomes in patients after allogeneic hematopoietic stem cell transplantation. , 2020, 8, A17.1-A17.		0
22	P03.16â€¦Functional defects in B-cells of patients with von-Hippel-Lindau Syndrome. , 2020, , .		0
23	P06.05â€¦IDO1-deleted CAR T cells show improved therapeutic efficacy in murine pancreatic cancer models. , 2020, , .		0
24	Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching. <i>Cancers</i> , 2020, 12, 2429.	3.7	5
25	ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells. <i>Oncogene</i> , 2020, 39, 3195-3205.	5.9	18
26	Effect of weight loss in patients with metastatic colorectal cancer treated within the randomized phase III FIRE-3 trial (AIO KRK 0306).. <i>Journal of Clinical Oncology</i> , 2020, 38, 87-87.	1.6	1
27	Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8521-8521.	1.6	2
28	Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTEÂ® Construct Stimulation in Vitro. <i>Blood</i> , 2020, 136, 44-45.	1.4	1
29	Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53. <i>Theranostics</i> , 2019, 9, 6047-6062.	10.0	43
30	PO-0890 Abscopal effects in metastasized cancer patients treated with PD-1 inhibition and radiation therapy. <i>Radiotherapy and Oncology</i> , 2019, 133, S470-S471.	0.6	0
31	Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma. <i>Oncolimmunology</i> , 2019, 8, 1535293.	4.6	97
32	Abscopal Effects in Radio-Immunotherapyâ€”Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition. <i>Frontiers in Pharmacology</i> , 2019, 10, 511.	3.5	56
33	Innovative Behandlungskonzepte mit Modulation der Mikroumgebung beim kutanen T-Zell-Lymphom. <i>Karger Kompass Dermatologie</i> , 2019, 7, 111-119.	0.0	0
34	Loss of ZBTB7A Enhances Glycolysis and Beta Oxidation in Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1453-1453.	1.4	1
35	Obesity exacerbates colitis-associated cancer via IL-6-regulated macrophage polarisation and CCL-20/CCR-6-mediated lymphocyte recruitment. <i>Nature Communications</i> , 2018, 9, 1646.	12.8	108
36	Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2653.	4.1	32

#	ARTICLE	IF	CITATIONS
37	Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2018, 132, 4429-4429.	1.4	0
38	Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation. <i>Oncology Research and Treatment</i> , 2017, 40, 262-269.	1.2	9
39	Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance. <i>Nature Communications</i> , 2017, 8, 14803.	12.8	55
40	Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. <i>Immunotherapy</i> , 2017, 9, 423-433.	2.0	9
41	Should we be combining local tumor therapies with immunotherapies as standard?. <i>Future Oncology</i> , 2017, 13, 1573-1575.	2.4	3
42	Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2017, 5, 730-743.	3.4	23
43	Serotonin Shapes the Migratory Potential of NK Cells – An in vitro Approach. <i>International Journal of Sports Medicine</i> , 2017, 38, 857-863.	1.7	9
44	IL-6/Stat3-Dependent Induction of a Distinct, Obesity-Associated NK Cell Subpopulation Deteriorates Energy and Glucose Homeostasis. <i>Cell Metabolism</i> , 2017, 26, 171-184.e6.	16.2	104
45	Antigen-presenting human B cells are expanded in inflammatory conditions. <i>Journal of Leukocyte Biology</i> , 2017, 101, 577-587.	3.3	28
46	Regulatory B10 cells display an altered homeostasis in acute graft-versus-host disease. <i>European Journal of Haematology</i> , 2017, 98, 128-133.	2.2	4
47	Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 44418-44433.	1.8	95
48	CD40-activated B cells induce anti-tumor immunity <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 27740-27753.	1.8	43
49	Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody. <i>European Journal of Haematology</i> , 2016, 97, 121-127.	2.2	17
50	Processing and MHC class II presentation of exogenous soluble antigen involving a proteasome-dependent cytosolic pathway in CD40-activated B cells. <i>European Journal of Haematology</i> , 2016, 97, 166-174.	2.2	13
51	FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission. <i>European Journal of Haematology</i> , 2016, 96, 475-482.	2.2	18
52	Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity. <i>Cell</i> , 2016, 165, 882-895.	28.9	167
53	Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 744-754.	3.4	131
54	OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. <i>European Journal of Haematology</i> , 2016, 96, 27-35.	2.2	52

#	ARTICLE	IF	CITATIONS
55	Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, e110-e116.	1.6	22
56	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. <i>Oncolmmunology</i> , 2016, 5, e1100789.	4.6	45
57	Physical exercise modulates the homeostasis of human regulatory T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1607-1610.e8.	2.9	65
58	Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 179-188.	4.4	65
59	NK cells link obesity-induced adipose stress to inflammation and insulin resistance. <i>Nature Immunology</i> , 2015, 16, 376-385.	14.5	407
60	Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality—a single institution experience. <i>Annals of Hematology</i> , 2015, 94, 1717-1725.	1.8	3
61	Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. <i>Leukemia</i> , 2015, 29, 981-984.	7.2	28
62	CD4+ T cell counts reflect the immunosuppressive state of CD4 helper cells in patients after allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 129-137.	1.8	1
63	Comprehensive characterization of PDL-1 and CTLA-4 in gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4056-4056.	1.6	0
64	Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. <i>Oncotarget</i> , 2014, 5, 4651-4664.	1.8	98
65	Inhibition of Protein Geranylgeranylation Specifically Interferes with CD40-Dependent B Cell Activation, Resulting in a Reduced Capacity To Induce T Cell Immunity. <i>Journal of Immunology</i> , 2014, 193, 5294-5305.	0.8	29
66	Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial. <i>Bone Marrow Transplantation</i> , 2014, 49, 410-415.	2.4	7
67	Overcoming tumor-mediated immunosuppression. <i>Immunotherapy</i> , 2014, 6, 973-988.	2.0	38
68	Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity. <i>Oncolmmunology</i> , 2014, 3, e954460.	4.6	19
69	Pretransplant Comorbidities Maintain Their Impact on Allogeneic Stem Cell Transplantation Outcome 5 Years Posttransplant: A Retrospective Study in a Single German Institution. <i>ISRN Hematology</i> , 2014, 2014, 1-7.	1.6	7
70	Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. <i>Nature Immunology</i> , 2014, 15, 423-430.	14.5	577
71	Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. <i>The Cochrane Library</i> , 2014, 2014, CD010189.	2.8	73
72	A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells. <i>Cytotherapy</i> , 2014, 16, 1537-1544.	0.7	12

#	ARTICLE	IF	CITATIONS
73	P60. Microtubule-depolymerising agents used in antibody-drug-conjugates induce anti-tumour immunity by stimulation of dendritic cells. , 2014, 2, .		0
74	Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells. Cancer Immunology Research, 2014, 2, 741-755.	3.4	134
75	18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. Leukemia and Lymphoma, 2014, 55, 811-816.	1.3	18
76	Allogeneic stem cell transplantation in patients with aggressive primary cutaneous T-cell lymphoma - a case series of the ADF working group - cutaneous lymphomas JDDG - Journal of the German Society of Dermatology, 2014, 12, 39-46.	0.8	6
77	Allogene Stammzelltransplantation bei Patienten mit aggressiven primär kutanen T-Zell-Lymphomen - eine Fallserie der ADF-Arbeitsgruppe - kutane Lymphome JDDG - Journal of the German Society of Dermatology, 2014, 12, 39-47.	0.8	9
78	p38 MAPK Controls Sensitivity Towards BH3 Mimetics By Regulating Mcl-1 Expression of Chronic Lymphocytic Leukemia in Hypoxia and Acquired Resistance. Blood, 2014, 124, 1947-1947.	1.4	0
79	CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application. Expert Review of Vaccines, 2013, 12, 631-637.	4.4	25
80	Comment on "Multiplex B Cell Characterization in Blood, Lymph Nodes, and Tumors from Patients with Malignancies" Journal of Immunology, 2013, 191, 4471.1-4471.	0.8	2
81	Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2013, 88, 178-186.	4.4	33
82	The ratio between dendritic cells and T cells determines whether prostaglandin E2 has a stimulatory or inhibitory effect. Cellular Immunology, 2013, 281, 62-67.	3.0	18
83	Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission. Journal of Clinical Oncology, 2013, 31, e59-e63.	1.6	62
84	Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: A systematic review. Critical Reviews in Oncology/Hematology, 2013, 85, 21-31.	4.4	31
85	Allogeneic Hematopoietic Stem Cell Transplantation: An Option for Long-Term Survival for Patients with Simultaneous Appearance of Myeloid and Lymphatic Malignancies. Acta Haematologica, 2013, 129, 135-136.	1.4	0
86	Cyclin A1, a promising tumor antigen: the devil is in the amino acids. Expert Review of Anticancer Therapy, 2013, 13, 243-245.	2.4	2
87	Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy? Immunotherapy, 2013, 5, 1039-1042.	2.0	3
88	CD30-Targeted Therapy with Brentuximab Vedotin and DLI in a Patient with T-Cell Posttransplantation Lymphoma. Transplantation, 2013, 96, e16-e18.	1.0	7
89	Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. The Cochrane Library, 2013, , CD008908.	2.8	13
90	Increased Functional T Cell Defects in Patients with low CD4 Counts after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 4588-4588.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Mast cells play a protumorigenic role in primary cutaneous lymphoma. <i>Blood</i> , 2012, 120, 2042-2054.	1.4	116
92	Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. <i>Blood</i> , 2012, 120, 1470-1472.	1.4	81
93	Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. <i>The Cochrane Library</i> , 2012, , CD009159.	2.8	28
94	Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. , 2012, 1, CD008908.		8
95	Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. <i>Annals of Hematology</i> , 2012, 91, 47-55.	1.8	23
96	CD30-Targeted Therapy with Brentuximab Vedotin Combined with Donor Lymphocyte Infusions Induce Sustained Clinical Remissions and Tumor Specific Immunity in a Series of Patients with Relapsed Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4213-4213.	1.4	2
97	Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. <i>Transplant Immunology</i> , 2011, 25, 163-166.	1.2	11
98	Activated primary human B cells efficiently induce early CD40L and CD107a expression in CD4+ T cells. <i>Blood</i> , 2011, 118, 5979-5980.	1.4	5
99	Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. <i>Bone Marrow Transplantation</i> , 2011, 46, 1045-1052.	2.4	70
100	Primed for Death: Hypoxia Sensitizes Primary CLL Cells towards Compounds Targeting Mitochondrial Integrity. <i>Blood</i> , 2011, 118, 1767-1767.	1.4	0
101	Human herpesvirus-6 as an inducer of porphyria cutanea tarda: implications from a case. <i>Transplant Infectious Disease</i> , 2010, 12, 432-436.	1.7	1
102	CD4+CD25highFoxP3+Regulatory T Cells Are Increased And Functionally Active After Antithymocyte Globulin Infusion And Allogeneic Stem Cell Transplantation In Humans â€” A Novel In Vivo Mechanism Of Action. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S220.	2.0	1
103	Reply to â€”The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rates in hematologic malignancy patients: outcome of a pilot clinical studyâ€” by Ning et al.. <i>Leukemia</i> , 2009, 23, 178-178.	7.2	13
104	Graft-versus-lymphoma effect in a 64-year-old caucasian woman after allogeneic stem-cell transplantation: a case report. <i>Journal of Medical Case Reports</i> , 2009, 3, 10.	0.8	4
105	Rituximab reduces the incidence of acute graft-versus-host disease. <i>Blood</i> , 2009, 113, 3130-3131.	1.4	37
106	Human parvovirus B19 infection with GvHD-like erythema in two allogeneic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2007, 39, 315-316.	2.4	16
107	Neurotoxicity upon infusion of dimethylsulfoxide-cryopreserved peripheral blood stem cells in patients with and without pre-existing cerebral disease. <i>European Journal of Haematology</i> , 2007, 78, 527-531.	2.2	38
108	Ectopic Overexpression of C/EBP-alpha in Primary Human Mesenchymal Stem Cells Is Sufficient To Induce Preadipocyte Determination but Not Terminal Differentiation without Hormonal Enhancement.. <i>Blood</i> , 2007, 110, 4116-4116.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Keratinocyte-Growth-Factor-Prophylaxis: Positive Effect on Intestinal Mucositis Following Autologous and Allogeneic Peripheral Blood Stem Cell Transplantation in Haemtological Malignancies: A Sequential Cohort Study.. Blood, 2007, 110, 4953-4953.	1.4	0
110	Rituximab Reduces the Incidence of Acute Graft Versus Host Disease in an Unselected Series of Twenty-One Patients Undergoing Allogeneic Stem Cell Transplantation at a Single Center.. Blood, 2006, 108, 2875-2875.	1.4	0
111	Reduced-Intensity Conditioning Including Fludarabine, Cyclophosphamide, Low Dose Total Body Irradiation and Anti-Thymocyte Globulin Providing Tolerable Toxicity and Patient-Adapted Treatment.. Blood, 2006, 108, 5250-5250.	1.4	0
112	Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood, 2005, 106, 3609-3617.	1.4	172
113	Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. Journal of Pathology, 2003, 201, 413-420.	4.5	134
114	Exercise interventions for adults with cancer receiving radiation therapy alone. The Cochrane Library, 0, , .	2.8	1